two-years follow up | three-years follow up | |||||||
---|---|---|---|---|---|---|---|---|
MCI-nc (n = 70, 90%) | MCI-c (n = 8,10%) | OR (95% CI) | P | MCI-nc (n = 62, 79%) | MCI-c (n = 16, 21%) | OR (95% CI) | P | |
SS-16 | ||||||||
< 8 | 18 (26%) | 6 (75%) | 0.12 (0.02–0.6) | 0.012 | 27 (44%) | 14 (88%) | 0.1 (0.02–0.5) | 0.006 |
≥ 8 | 52 (74%) | 2 (25%) | 35 (56%) | 2 (12%) | ||||
Aβ1–42, pg/ml | ||||||||
< 14.02 | 43 (61%) | 7 (88%) | 11.1 (1.3–95.7) | 0.028 | 41 (66%) | 3 (19%) | 8.5 (2.2–33) | 0.002 |
≥ 14.02 | 27 (39%) | 1 (12%) | 21 (34%) | 13 (81%) | ||||
ApoE ε4 carrier | ||||||||
(+) | 12 (17%) | 2 (25%) | 1.6 (0.29–9.0) | 0.590 | 10 (16%) | 4 (25%) | 1.7 (0.5–6.5) | 0.415 |
(−) | 58 (83%) | 6 (75%) | 52 (84%) | 12 (75%) |